New pill tested for deadly lung scarring disease
NCT ID NCT07225296
Summary
This is the first human study testing a new oral medication called GNS-3545, which is being developed to treat idiopathic pulmonary fibrosis—a serious disease that causes progressive lung scarring. The study will enroll 72 healthy adults to check the drug's safety, how it moves through the body, and how it's affected by food. This early phase focuses on establishing safe dosage levels before testing in patients with the actual disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pharmaron CPC, Inc.
RECRUITINGBaltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.